PT-141

PT-141, also known as bremelanotide, is a synthetic peptide that interacts with melanocortin receptors. This product information page provides essential details about its identity, labelled strength, specifications and supporting documentation.

At Peptide Insight, customers can review these details to understand the listed product. However, independently supplied peptide preparations should not be confused with approved pharmaceutical medicines.

PT-141 Product Overview

This listing identifies PT-141 with a strength of 10mg.

Before selecting the item, customers should confirm its chemical identity, manufacturer and packaging details. Additionally, the information on the product label should match the accompanying documentation.

Explore our Peptide Products collection to view related listings and compare their individual specifications.

PT-141 Specifications and Strength

Clear product specifications help customers identify the precise formulation and understand what the listing represents.

Product name: PT-141

Alternative name: Bremelanotide

Strength: 10mg

Peptide classification: Melanocortin receptor agonist

Product form: Confirm from the packaging

Manufacturer: Confirm supplier information

Package contents: Verify the actual contents

Storage: Follow verified manufacturer instructions

Furthermore, customers should check the batch number and expiration date when applicable.

Visit the Peptide Insight shop to browse other available product information.

Product Quality and Documentation

Accurate documentation helps customers understand the identity and characteristics of a product.

First, review the manufacturer’s specifications and confirm the ingredient information.

Next, examine any available certificate of analysis. Ensure that the document corresponds to the actual batch rather than an unrelated preparation.

Moreover, verify claims about purity, testing and quality before relying on them. Product photographs alone cannot establish these characteristics.

For additional website information, visit Peptide Insight.

PT-141 Safety and Regulatory Information

The FDA has approved a specific bremelanotide medicine called Vyleesi for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women.

However, that approval does not extend to independently supplied 10mg peptide preparations.

The approved medicine can cause nausea, temporary increases in blood pressure and skin pigmentation changes. It is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.

Customers can consult the official bremelanotide prescribing information for additional safety information.

Product Availability and Customer Information

Before considering a purchase, verify the product’s identity, labelled quantity, supporting documentation and applicable legal requirements.

Additionally, contact the supplier if essential specifications remain unclear.

This listing does not establish that an independently supplied preparation is an approved medicine, equivalent to Vyleesi or suitable for human administration.